Clinical Trials Logo
NCT number NCT03195712
Study type Observational
Source St. Luke's-Roosevelt Hospital Center
Contact
Status Completed
Phase N/A
Start date September 4, 2012
Completion date September 30, 2016

Clinical Trial Summary

The study team's research fills the gap in the obesity literature where BMI with a cut point of 35 is frequently used to show the association between BMI and metabolic syndrome biomarkers. The study team was unable to locate any papers that showed the association between metabolic syndrome biomarkers and BMI from 35 to 69.9, and especially graphically as this clinical team has presented.


Clinical Trial Description

A positive association between BMI and metabolic health risk is often presented graphically as a J-shaped curve with BMI on the x-axis and the biomarker of interest on the y-axis. However, BMI is frequently presented in the literature with a cut point of 35 on the x-axis, leading to the assumption that the steep association continues beyond a BMI of 35. This presentation does not capture the metabolically healthy individual with obesity.

In the population of men and women with class II and II obesity who the clinical team studied, it was examined that the association between BMI as a continuous variable from 35 to 69.9 and metabolic syndrome biomarkers (total-, low density, and high density cholesterol, triglycerides, systolic and diastolic blood pressure, fasting blood glucose, and glycosylated hemoglobin), the study team found no evidence for a positive correlation between BMI and TC, LDL-C, TG, and FBG. And while the study team did find positive and significant correlations between BMI and HDL-C, SBP, DBP, and HgbA1C, the effect sizes were small and arguably clinically insignificant.

The study team's research fills the gap in the obesity literature where BMI with a cut point of 35 is frequently used to show the association between BMI and metabolic syndrome biomarkers. The clinical team was unable to locate any papers that showed the association between metabolic syndrome biomarkers and BMI from 35 to 69.9, and especially graphically as this clinical team has presented.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Completed NCT02235961 - Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects Phase 1
Recruiting NCT00341406 - Fat Cell Size in Insulin Resistance N/A
Recruiting NCT02918279 - Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Phase 3
Completed NCT00494767 - Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs Phase 1
Completed NCT01222793 - Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia N/A
Completed NCT01967563 - Study of the Effect of a Very-Low-Carbohydrate Diet on Energy Expenditure N/A
Completed NCT00976105 - Effects of Repeat Dosing of GSK1521498 Phase 1
Completed NCT00535600 - Effects of Bariatric Surgery on Insulin N/A
Not yet recruiting NCT03104205 - MOWI Home-Based Pilot N/A
Recruiting NCT03104192 - MOWI Research Pilot N/A
Recruiting NCT03130244 - Endoscopic Procedure for Jejunal to Ileal Diversion to Treat Type 2 Diabetes N/A
Not yet recruiting NCT02621086 - Cellodextrin Tolerability Study N/A
Not yet recruiting NCT03238794 - Bariatric Surgery Versus Diet Alone in the Bile Acid Pathway and Weight Loss N/A
Not yet recruiting NCT03251833 - The Impact of Obesity on Maternal and Perinatal Outcomes N/A
Not yet recruiting NCT02957539 - Financial vs. Non-Financial Rewards for Weight Loss and Weight Maintenance N/A
Not yet recruiting NCT03036800 - Saxenda in Obesity Services (STRIVE Study) Phase 4
Not yet recruiting NCT03047018 - Open Trial Obesity CHANGE Program ASD N/A
Not yet recruiting NCT02924636 - Electronic-personalized Program for Obesity in Pregnancy to Improve Delivery N/A
Not yet recruiting NCT03236337 - Effectiveness of MOVI Interventions on Adiposity, Cognition and Subclinical Atherosclerosis: MOVI-daFit! N/A